AstraZeneca and Hutchmed Initiate P-III SANOVO Trial for Orpathys (savolitinib) + Tagrisso (osimertinib) as a 1L Therapy for Non-small Cell Lung Cancer in China
Shots:
- The companies initiate P-III SANOVO study to evaluates the efficacy & safety of Orpathys in combination with AstraZeneca’s Tagrisso (irreversible EGFR TKI) vs Tagrisso alone in patients with NSCLC whose tumors harbor EGFR mutation and overexpress MET. The first patient was dosed on Sept 7- 2021
- The 1EPs of the study is m-PFS as assessed by investigators & other EPs include m-PFS as assessed by IRC- m-OS- ORR- DoR- DCR- time to response- and safety
- In 2011- the companies collaborated to jointly develop & commercialize savolitinib where Hutchmed will lead marketing authorization- manufacturing & supply of the therapy in China & AstraZeneca is responsible for the commercialization globally
Ref: Globe Newswire | Image: Pharmaletter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com